A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL)

Overview

This is a randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care.

.

Full Title of Study: “GM-18 – A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine Using Open Label Non-invasive Vagal Nerve Stimulation, Versus Standard of Care (REAL)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 1, 2020

Detailed Description

A randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care.

Eligible subjects will participate in a 4 week run-in period after which they will be randomized (1:1) to either nVNS and standard of care (nVNS group) or standard of care (SOC group) for 12 weeks. The nVNS group will use the nVNS device preventatively and acutely for the treatment of migraine. The SOC group will continue to use their regular standard of care migraine treatment medications for the duration of the 12 week randomized period.

Interventions

  • Device: non-invasive vagus nerve stimulation
    • non-invasive vagus nerve stimulation using the gammaCore Sapphire device

Arms, Groups and Cohorts

  • Experimental: non-invasive Vagus Nerve Stimulation
    • nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
  • No Intervention: Standard of Care
    • Standard of Care treatment

Clinical Trial Outcome Measures

Primary Measures

  • Reduction in number of migraine days during the last four weeks in the twelve-week randomized period compared with the four-week run-in period
    • Time Frame: The last four weeks in the randomization period compared to the four week run-in period.
    • Reduction in number of migraine days during the last four weeks in the twelve-week randomized period compared with the four-week run-in period

Secondary Measures

  • Reduction in number of headache days during the last four-weeks in the twelve-week randomized period compared to the four-week run-in period
    • Time Frame: The last four weeks in the randomization period compared to the four week run-in period.
    • Reduction in number of headache days during the last four-weeks in the twelve-week randomized period compared to the four-week run-in period
  • Reduction in number of migraine days and headache days (separately)
    • Time Frame: 12 week randomised period
    • Reduction in number of migraine days and headache days (separately) during weeks 1 through 4, 5 through 8 in the 12 week randomised period
  • Rate of responders for the nVNS group compared to the standard of care group.
    • Time Frame: The last four weeks in the randomization period compared to the four week run-in period.
    • Rate of responders (mean reduction in migraine days during the last four weeks in the twelve-week randomization period compared to the four-week run-in period dichotomized as <25% vs. ≥25%, <50% vs ≥50% and <75% vs ≥75%, separately) for the nVNS group compared to the standard of care group.
  • Acute treatment response for nVNS and standard of care therapies
    • Time Frame: 12 week randomised period
    • Acute treatment response for nVNS and standard of care therapies at 30, 60 and 120 minutes post-treatment, for all treated migraine attacks in the twelve-week randomized period
  • Consistency of response
    • Time Frame: 12 week randomised period
    • Consistency of response as defined as the percentage of subjects who achieve treatment response in 25%, 50% and 75% or greater of their attacks, in subjects treating at least two attacks, for nVNS and standard of care therapies for all treated migraine attacks during the randomized period
  • Safety and tolerability of nVNS as measured by adverse events
    • Time Frame: 12 week randomised period
    • Safety and tolerability of nVNS as measured by adverse events

Participating in This Clinical Trial

Inclusion Criteria

  • Is 18 years of age or above.
  • Has been previously diagnosed with episodic or chronic migraine (with or without aura) in accordance with the ICHD-3 Classification criteria.
  • Experience at least 6 and no more than 24 headache days per month and a minimum of 4 migraine attacks per month (over the last 3 months).
  • Has age of onset of migraine less than 50 years old.
  • Stable regime for any migraine preventative medications for the last 3 months and agrees to maintain stable regime for duration of the study.
  • Agrees to and in clinician opinion is able to use the nVNS device as intended, follow all of the requirements of the study including follow-up visit requirements, record required study data in the subject dairy, and other self-assessment questionnaires.
  • Availability of internet/Web access for Web-based e-diary completion
  • Is able to provide written Informed Consent.

Exclusion Criteria

  • Requires use of oral or injectable steroids for concomitant medical condition that in the opinion of the investigator will interfere with the study.
  • Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or significant head trauma.
  • Has a structural abnormality at the nVNS treatment site (e.g. lymphadenopathy previous surgery or abnormal anatomy).
  • Has pain at the nVNS treatment site (e.g. dysesthesia, neuralgia and/or cervicalgia).
  • Has other significant pain problem (e.g. cancer pain or other head or facial disorder) that in the opinion of the investigator may confound the study assessments
  • Has known or suspected severe cardiac disease (e.g. symptomatic coronay artery disease, prior myocardial infarction, congestive heart failure (CHF)).
  • Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior cartoid endarterectomy or other vascular neck surgery).
  • Has known or suspected own and/or family history of cardiac disease (including but not limited to ischemic heart disease, rhythm disturbances, congenital abnormalities cardiac myopathies), or presents risk factors strongly associated with risk for developing cardiologic abnormalities that in the opinion of the investigator might compromise subjects safety using n-VNS.
  • Has had a cervical vagotomy.
  • Has uncontrolled high blood pressure (systolic >160 diastolic > 100 after 3 repeated measurements within 24 hours).
  • Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, cochlear implant, Spehnopalatine ganglion stimulator or Occiptial nerve stimulator).
  • Has been implanted with metal cervical spine hardware or has a metallic implant near the nVNS stimulation site (e.g. in the head, neck of thorax).
  • Presents a suspicion of secondary headache.
  • Previous diagnosis of medication overuse headache within the last 3 months
  • Has a history of syncope (within the last 1 year).
  • Has a history of seizures (within the last 1 year).
  • Has a known or suspicion of substance abuse or addiction (within the last 1 year).
  • Has initiated medications for migraine prophylaxis in the previous 30 days, or in the case of Botulinum toxin and monoclonal antibodies against CGRP injections in the previous 90 days.
  • Has failed an adequate trial (two months or greater) of at least 3 classes of a drug therapy for the prophylaxis of migraine.
  • Is pregnant or of childbearing years and is unwilling to use and accepted form of birth control (condom or contraceptive pill).
  • Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
  • Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self assessments is compromised (e.g. homeless, developmentally disabled and prisoner).
  • Has previously used the gammaCore device within the last 3 months.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ElectroCore INC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alexandra Sinclair, MD, Principal Investigator, University of Birmingham

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.